1st Quarter - Report

THE MCMANUS GROUP for EMD SERONO, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$50,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 20, 2016 $50,000 Replaced
1st Quarter - Amendment Jun 30, 2016 $50,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Tax issues affecting pharmaceutical products, particularly new expenditures for fertility products

LobbyistCovered position, as disclosed
JOHN MCMANUS —
CHASE M THOMAS —
BARRETT THORNHILL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

General pharmaceutical coverage and reimbursement issues, health exchange policy; issues and activities affecting neurodegenerative and fertility products

LobbyistCovered position, as disclosed
JOHN MCMANUS —
BARRETT THORNHILL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products.Advocacy regarding proposed Part B demo (81 FR 13229).

LobbyistCovered position, as disclosed
JOHN MCMANUS —
BARRETT THORNHILL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.